Results 31 to 40 of about 10,758 (225)
Frontiers in Immunology, 2023 Immune checkpoint blockade represents the latest revolution in cancer treatment by substantially increasing patients’ lifetime and quality of life in multiple neoplastic pathologies.
Chiara Ursino +4 more
doaj +1 more source
Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience. [PDF]
Cancers (Basel)Purpose: We report a 10-year experience in cancer therapy with concomitant treatment of percutaneous thermal ablation (PTA) and immune checkpoint blockers (ICBs). Material and methods: This retrospective cohort study included all patients at a single tertiary cancer center who had received ICBs at most 90 days before, or 30 days after, PTA. Feasibility
Bonnet B +10 more
europepmc +3 more sources
The Cellular and Molecular Immunotherapy in Prostate Cancer
Vaccines, 2022 In recent history, immunotherapy has become a viable cancer therapeutic option. However, over many years, its tenets have changed, and it now comprises a range of cancer-focused immunotherapies. Clinical trials are currently looking into monotherapies or
Anirban Goutam Mukherjee +9 more
doaj +1 more source
Scientific Reports, 2018 DNA vaccination against cancer has become a promising strategy for inducing a specific and long-lasting antitumor immunity. However, DNA vaccines fail to generate potent immune responses when used as a single therapy.
Alessandra Lopes +7 more
doaj +1 more source
Antibiotic exposure windows and the efficacy of immune checkpoint blockers in patients with cancer: a meta-analysis [PDF]
Annals of Palliative Medicine, 2021 Immune checkpoint blockers (ICBs) improve the survival of patients with cancer, but primary or acquired drug resistance is inevitable. Intestinal microorganisms play an important role in immunotherapy and antitumor response, and antibiotic use can cause changes in intestinal microbial abundance and diversity.
Litang, Huang +7 more
openaire +2 more sources
The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma
Biomedicines, 2022 Immunotherapies with immune checkpoint inhibitors or adoptive cell transfer have become powerful tools to treat cancer. These treatments act via overcoming or alleviating tumor-induced immunosuppression, thereby enabling effective tumor clearance ...
Mitrajit Ghosh +2 more
doaj +1 more source
Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology
Frontiers in Oncology, 2018 The tumor microenvironment (TME) is a multifaceted ecosystem characterized by profound cellular heterogeneity, dynamicity, and complex intercellular cross-talk.
Francesca Finotello, Federica Eduati
doaj +1 more source
npj Precision Oncology, 2021 A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer.
Yves Boucher +10 more
doaj +1 more source
Immune checkpoint: The novel target for antitumor therapy
Genes and Diseases, 2021 Inhibitory checkpoint molecules include programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), human endogenous retrovirus-H Long terminal repeat-associating 2 (HHLA2), B7 homolog 4 protein (B7 ...
Xianghu Jiang +3 more
doaj +1 more source
Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. [PDF]
Emerg Top Life Sci, 2017 Targeting of immune checkpoint blockers (ICBs), such as cytotoxic T-lymphocyte antigen-4 and programmed-death 1/programmed-death ligand 1, has dramatically changed the landscape of cancer treatment. Seeing patients who were refractory to conventional therapy recover after immunotherapy, with high rates of objective durable responses and increased ...
Trono P +4 more
europepmc +4 more sources